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The Photosensitizing Clinical Agent Verteporfin is an Inhibitor of 
SPAK and OSR1 Kinases 
Mubarak A. AlAmri,[b] Hachemi Kadri,[a] Luke J. Alderwick,[c] Mark Jeeves,[d] Youcef Mehellou,*[a]  
 
Abstract: SPAK and OSR1 are two serine/threonine protein kinases 
that play important key roles in regulating ion homeostasis. Various 
SPAK and OSR1 mouse models exhibited reduced blood pressure. 
Herein, we report the discovery of Verteporfin, a photosensitizing 
agent used in photodynamic therapy, as a potent inhibitor of SPAK 
and OSR1 kinases. We show that Verteporfin binds the kinase 
domains of SPAK and OSR1 and inhibit their catalytic activity in an 
ATP-independent manner. In cells, Verteporfin was able to suppress 
the phosphorylation of the ion co-transporter NKCC1, a downstream 
physiological substrate of SPAK and OSR1 kinases. Kinase panel 
screening indicated that Verteporfin inhibited a further eight protein 
kinases more potently than SPAK and OSR1. Although Verteporfin 
has largely been studied as a modifier of the Hippo signaling pathway, 
this work indicates that the WNK-SPAK/OSR1 signaling cascade is 
also a target of this clinical agent. This finding could explain the 
fluctuation in blood pressure noted in patients and animals treated 
with this drug. 
Introduction 
The STE20/SPS1-related proline/alanine-rich kinase (SPAK) and 
the oxidative-stress-responsive kinase 1 (OSR1) are two closely 
related serine/threonine protein kinases that play essential roles 
in regulating ion homeostasis and blood pressure.[1] SPAK and 
OSR1 kinases are 68% identical in sequence and share a 92-
amino acids highly conserved carboxy-terminal (CCT) domains 
(aa. 436-527 for OSR1 and 456-547 for SPAK), which are 
themselves 79% identical in sequence.[2] They are activated by 
osmotic stress or hypotonic (low chloride) environments resulting 
in phosphorylation at their T-loops by a family of protein kinases 
known as with no lysine (WNK) kinases 1-4 (Figure 1A).[3] Upon 
WNK activation, SPAK and OSR1 kinases bind to the scaffolding 
protein Mouse Only protein 25 (MO25),[4] of which in humans two 
isoforms a and b are expressed, resulting in a further 80- to 100-
fold increase in their in vitro kinase activity (Figure 1A).[5] 
Subsequently, SPAK and OSR1 kinases in complex with MO25 
phosphorylate an array of ion co-transporters such as the Na+-K+-
Cl- co-transporters 1 and 2 (NKCC1 and 2), the Na+-Cl- co-
transporter (NCC) and K+-Cl- co-transporter (KCC), which are the 
molecular targets of the antihypertensive loop and thiazide 
diuretics (Figure 1A).[1] 
As genetic mutations in the WNK protein kinases, which regulate 
the function of SPAK and OSR1, cause an inherited form of 
hypertension in humans known as Gordon’s syndrome,[6] SPAK 
and OSR1 have consequently been implicated in the regulation of 
blood pressure in humans.[7] The link between SPAK and OSR1 
kinases and blood pressure was further strengthened by the 
discovery that the two E3 ubiquitin ligases, Cullin3 and KLHL3, 
which regulate the expression levels of WNK kinases,[8] are also 
mutated in some humans with an inherited form of hypertension[9]. 
To provide an in vivo evidence of the direct involvement of SPAK 
and OSR1 kinases in regulating blood pressure, numerous SPAK 
knock-in and knock-out mouse models were generated and these 
exhibited a reduction in blood pressure.[7] Such finding has 
stimulated interest in the discovery of new compounds that inhibit 
WNK, SPAK and OSR1 kinases and offer advantageous 
antihypertensive effects. To date, only few compounds that inhibit 
these kinases have been reported,[10] with the most promising and 
potent inhibitors being of WNK kinases[11] instead of SPAK and 
OSR1. Nevertheless, a selection of small molecules such as 
STOCK506099, Closantel and Rafoxanide have been reported as 
SPAK and OSR1 kinase inhibitors with moderate potency in vitro 
(Figure 1B).[12] These inhibitors could be divided into two groups; 
non-ATP competitive inhibitors and protein-protein interaction 
inhibitors. The first group of inhibitors, which includes STOCK1S-
50699 and STOCK2S-26016, bind SPAK and OSR1 CCT 
domains and prevent their binding to the upstream WNK kinases 
and hence inhibiting their activation.[12a] The second group 
includes STOCK1S-14279, Closantel and Rafoxanide, which 
inhibit SPAK and OSR1 activity by binding to an allosteric site on 
their CCT domains and do not seem to interfere with the binding 
to WNK kinases.[12b, 12c]  
Encouraged by the amenability of targeting and inhibiting SPAK 
and OSR1 kinases by small molecules and the potential of these 
inhibitors as antihypertensive agents, we embarked on 
discovering novel SPAK and OSR1 kinase inhibitors using a high-
throughput screening (HTS) approach. 
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Results  
Optimization of OSR1 HTS assay. 
Most of the reported studies into the in vitro SPAK and OSR1 
kinase activity employ radioactive ATP,[2, 5, 13] so we first had to 
develop and optimize a non-radioactive in vitro SPAK or OSR1 
kinase assay compatible with HTS technologies. For this, we used 
Promega’s ADP-GloÔ kinase assay,[14] which employs a 
luminescent ADP detection system instead of radioactive ATP. 
We previously used this assay for determining SPAK and OSR1 
kinase activity in vitro though it was not optimized for HTS 
screening at that stage.[12c] For our HTS kinase assay, we decided 
to use E.coli-expressed full length human OSR1 T185E (1-527) 
(Supplementary Figure S1), where threonine 185 was mutated 
into glutamic acid to mimic WNK phosphorylation at this site, 
making the kinase constitutively active in vitro as previously 
reported (Supplementary Figure S2).[15] The choice of OSR1 
T185E instead of SPAK T233E was due to the superior in vitro 
kinase activity exhibited by OSR1 T185E compared to SPAK 
T233E.[5, 15] As an in vitro OSR1 T185E substrate, we decided to 
use a fragment of the bacterially expressed human NKCC2 (1–
174) encompassing the N-terminal cytoplasmic domain. This is 
readily obtained from E.coli expression systems (Supplementary 
Figure S3) and it was shown previously to be phosphorylated by 
OSR1 T185E in vitro at various threonine residues, precisely T95 
and T100.[16] The optimal conditions for the 384-well plate HTS-
compatible in vitro kinase assay were 0.2 µM OSR1 T185E, 5 µM 
human NKCC2 (1–174) (used as substrate), 0.1 mM ATP and 10 
mM MgCl2. These conditions gave an assay with a z’ factor of 
0.78 (minimum ≥ 0.5), signal-to-noise ratio (S/N) and signal-to-
background ratio (S/B) were 94.6 (minimum > 10) and 16.9 
(minimum > 3), respectively, indicating the robustness of our 
assay (Supplementary Figure S4).[17] Post-screening, the z’ 
factor, signal window (SW), and coefficient of variation (CV) of 
each plate were calculated and compared with the minimum pass 
criteria to evaluate the quality of screening data. All parameters 
exceeded the minimum pass limits (see Experimental Section).[17]  
Screening library of 1,200 compounds 
Once the assay was optimized, we screened an in-house library 
of 1,200 FDA-approved compounds at a single concentration of 
20 µM. This primary screen led to the identification of eighteen 
hits that achieved ³ 40% inhibition of OSR1 T185E kinase activity 
in vitro (Figure 2A). To verify these initial hits, they were 
subsequently screened at 10 and 50 μM (Figure 2B). Only seven 
out of the initial eighteen hits were then found to inhibit OSR1 
T185E in vitro in a dose-dependent manner giving an overall hit 
rate from this HTS exercise of 0.58%. Subsequently, the IC50 
values of the seven verified hit compounds were determined using 
two different OSR1 T185E substrates, the bacterially expressed 
human NKCC2 (1-174) fragment, which we used in the HTS 
assay and an 18-mer peptide termed CATCHtide[2] that had been 
developed previously as a SPAK and OSR1 peptide substrate 
(Figure 2C). Verteporfin (Figure 2D), a benzoporphyrin derivative 
approved for use as a photosensitizer in photodynamic therapy,[18] 
Figure 1. A summary of WNK-SPAK/OSR1 signaling cascade and the various reported SPAK and OSR1 kinase inhibitors. (A) WNK kinases, which are 
mutated in some humans with an inherited form of hypertension, become activated under osmotic stress and phosphorylate SPAK and OSR1 kinases. These 
subsequently bind the scaffolding protein MO25 and phosphorylate a selection of sodium, potassium and chloride ion co-transporters leading either to their 
activation or inhibition. (B) Chemical structures of reported compounds that inhibit SPAK and OSR1 kinases by binding to their C-terminal domain and either acting 
as allosteric inhibitors (Closantel, STOCK1S-14279 and Rafoxanide) or inhibitors of SPAK and OSR1 binding to their upstream WNK kinases (STOCK1S-50699 
and STOCK2S-26016). 
    
 
 
 
 
 
emerged as the most potent in vitro inhibitor of OSR1 T185E, IC50 
= 0.207 µM (Figure 2C). Verteporfin exhibited equally potent 
inhibition of the constitutively active, bacterially expressed human 
full length SPAK T233E, IC50 = 0.330 µM (Supplementary Figure 
S5). Such potency warranted further characterization of 
Verteporfin as a novel inhibitor of OSR1 and SPAK kinases. 
Notably, Verteporfin is a mixture of two regioisomers where one 
of the carboxylic acids is esterified and the other is free as shown 
in Figure 2D. The compound used in the screening was a 50:50 
mixture of the two regioisomers and the subsequent studies in this 
report employ commercially available Verteporfin, which is a 
50:50 mixture of the regioisomers and has an overall 94% purity. 
Verteporfin inhibits SPAK and OSR1 in vitro 
To understand the mechanism by which Verteporfin inhibits 
OSR1 T185E, we run the in vitro kinase assay using three 
different concentrations of ATP (0.01 mM, 0.1 mM and 1 mM). 
The results showed that Verteporfin inhibition of OSR1 T185E 
was not significantly influenced by the concentration of ATP 
indicating that Verteporfin inhibits OSR1 T185E in an ATP-
independent manner (Figure 3A). Given that Verteporfin has a 
benzoporphyrin structure with basic nitrogen atoms, we next 
explored if these would chelate the Mg+2 from the kinase assay 
and this is what led to the observed inhibition. For this, the in vitro 
kinase assay was run using two different concentrations of MgCl2, 
1 mM and 50 mM. The results showed that the inhibition of OSR1 
T185E by Verteporfin was not significantly affected by the 
concentration of MgCl2 suggesting that Verteporfin is not 
chelating the Mg+2 in the kinase assay (Figures 3B and 3C). To 
further explore this, we next studied the ability of Verteporfin to 
inhibit the mammalian sterile 20 like kinase 3 (MST3), which 
belongs to the same family (Ste20) of protein kinases as SPAK 
and OSR1.[19] The results showed that Verteporfin did not inhibit 
MST3 even at 100 µM further confirming the inability of 
Verteporfin to act as a Mg+2 chelator in these in vitro kinase 
assays (Figure 3D). Notably, two commercially available 
analogues of Verteporfin, which contain the porphyrin ring did not 
inhibit OSR1 T185E in vitro (Supplementary Figure S6). Finally, 
to ensure that Verteporfin was not acting as a protein aggregator, 
the in vitro kinase assay was run in the absence or presence of 
0.05% of the detergent Tween-20. The data showed that there 
was no dramatic change in the IC50 values in both cases indicating 
that the observed inhibitory effect was not due to the induction of 
protein (OSR1 T185E) aggregation by Verteporfin (Figures 3E 
and 3F).  
Figure 2. Identification of Verteporfin as an inhibitor of OSR1 T185E in vitro. (A) Scatterplots of the primary screening using the developed assay. Dashed 
line shows the ‘hit’ selection criteria (³ 40% Inhibition of OSR1 T185E kinase activity). (B) The secondary screening using the developed assay. Compounds were 
screened at two concentrations 10 and 50 µM in triplicate. Data presented as a mean ± SD. (C) In vitro IC50 values of true hit OSR1 T185E inhibitors using the 
peptide substrate CATCHtide or the NKCC2 fragment (1-174). (D) Chemical structure of Verteporfin, the top hit from the HTS exercise. 
 
0         100       200      300      400      500      600      700       800      900    1000    1100    1200              
N
or
m
al
ise
d 
in
hi
bi
tio
n 
(%
)
0
-20
-40
-60
20
40
60
80
100
Lu
m
in
es
ce
nc
e 
(R
LU
)
0
5 x 103
1 x 104
1.5 x 104
2 x 104
2.5 x 104
3 x 104
DM
SO
Clo
sa
nt
el 
(50
 µM
) 
Ra
fox
an
ide
 (5
0 µ
M)
 
Su
lfa
gu
an
idi
ne
 (1
0 µ
M)
 
Su
lfa
gu
an
idi
ne
 (5
0 µ
M)
 
Ch
lor
he
xid
ine
 (1
0 µ
M)
 
Ch
lor
he
xid
ine
 (5
0 µ
M)
 
Ch
ica
go
 sk
ye
 bl
ue
 6B
 (1
0 µ
M)
 
Ch
ica
go
 sk
ye
 bl
ue
 6B
 (5
0 µ
M)
 
Be
ta-
Es
cin
 (1
0 µ
M)
 
Be
ta-
Es
cin
 (5
0 µ
M)
 
Ale
xid
ine
 di
hy
dr
oc
hlo
rid
e (
10
 µM
) 
Ale
xid
ine
 di
hy
dr
oc
hlo
rid
e (
50
 µM
) 
Th
on
zo
niu
m 
br
om
ide
 (1
0 µ
M)
 
Th
on
zo
niu
m 
br
om
ide
 (5
0 µ
M)
 
To
rem
ife
ne
 (1
0 µ
M)
 
To
rem
ife
ne
 (5
0 µ
M)
 
Ve
rte
po
rfi
n (
10
 µM
) 
Ve
rte
po
rfi
n (
50
 µM
) 
Flo
rfe
nic
ol 
(10
 µM
) 
Flo
rfe
nic
ol 
(50
 µM
) 
Me
th
yl 
be
nz
th
on
ium
 ch
lor
ide
 (1
0 µ
M)
 
Me
th
yl 
be
nz
th
on
ium
 ch
lor
ide
 (5
0 µ
M)
 
Ni
fur
ox
az
ole
 (1
0 µ
M)
 
Ni
fur
ox
az
ole
 (5
0 µ
M)
 
Hy
dr
oc
hh
lor
ot
hiz
ide
 (1
0 µ
M)
 
Hy
dr
oc
hh
lor
ot
hiz
ide
 (5
0 µ
M)
 
Py
rim
eth
am
ine
 (1
0 µ
M)
 
Py
rim
eth
am
ine
 (5
0 µ
M)
 
Fa
dr
oz
ole
 hy
dr
oc
hlo
rid
e (
10
 µM
) 
Fa
dr
oz
ole
 hy
dr
oc
hlo
rid
e (
50
 µM
) 
Ni
lva
dip
ine
 (1
0 µ
M)
 
Ni
lva
dip
ine
 (5
0 µ
M)
 
Pra
ziq
an
tal
 (1
0 µ
M)
 
Pra
ziq
an
tal
 (5
0 µ
M)
 
Gl
icl
az
ide
 (1
0 µ
M)
 
Gl
icl
az
ide
 (5
0 µ
M)
 
Th
eo
ph
yli
ne
 m
on
oh
yd
rat
e (
10
 µM
) 
Th
eo
ph
yli
ne
 m
on
oh
yd
rat
e (
10
 µM
) 
A.
B.
C. D.
N HN
O
O
O
O
NNH
OOO O
R1 R2
R1 = CH3 and R2 = H (50%).
R1 = H and R2 = CH3 (50%).
    
 
 
 
 
 
As the kinase activity of SPAK and OSR1 is significantly 
increased by binding to the scaffolding protein MO25,[5] we 
explored the effect of Verteporfin on the MO25-dependent 
activation of SPAK T233E and OSR1 T185E in vitro. The results 
showed that Verteporfin did not affect the ability of MO25 to 
activate OSR1 T185E in vitro (Supplementary Figure S7). Since 
some reports have implicated that the biological activity of 
Verteporfin is affected by light,[20] we also studied whether light 
has an effect on Verteporfin’s ability to inhibit OSR1 T185E in vitro. 
The results showed that carrying the in vitro kinase assay in the 
dark led to a 3-fold decrease in the ability of Verteporfin to inhibit 
OSR1 T185E in vitro (Supplementary Figure S8).   
Verteporfin selectivity across 140 protein kinases 
To establish the selectivity of Verteporfin towards SPAK and 
OSR1 kinases, it was run in the MRC PPU Premier Screen of 140 
protein kinases (http://www.kinase-
screen.mrc.ac.uk/services/premier-screen) at a single 
concentration of 1 µM. Beyond SPAK and OSR1, the primary HTS 
screening exercise revealed eight other protein kinases that were 
potently inhibited with a kinase activity suppression of ³ 70% at 1 
µM. These were the Inhibitor of Nuclear Factor Kappa-B Kinase 
subunit Epsilon (IKKe), Mammalian STE20-like Protein Kinase 2 
(MST2), Germinal Center Kinase (GCK), Mitogen-Activated 
Protein Kinase Kinase Kinase Kinase 3 (MAP4K3), Mitogen-
Activated Protein Kinase 1 (MLK1), Unc-51 Like Autophagy 
Activating Kinase 1 (ULK1), ULK2 and the Lymphocyte-Specific 
Protein Tyrosine Kinase (Lck). Further studies into the inhibition 
of these two important protein kinases are being conducted and 
will be reported in the future. 
Verteporfin inhibits SPAK and OSR1 kinases in cells 
Next, the ability of Verteporfin to inhibit SPAK and OSR1 kinases 
in cells was established (Figure 4). HEK293 cells, which express 
endogenous WNKs, SPAK, OSR1 and MO25 were first treated 
for 30 minutes with Verteporfin at various concentrations, 10 µM 
STOCK1S-50699,[12a] a WNK-signaling inhibitor, or 20 µM 
Closantel, a direct allosteric SPAK/OSR1 kinase inhibitor[12b]. 
After that, the cells were treated with hypotonic buffer for 30 
minutes to activate SPAK and OSR1[3a].  Subsequently, the cells 
were lysed and probed for SPAK/OSR1-phosphorylation of 
NKCC1 at residues T203, T207 and T212. As expected, both 
Figure 3. In vitro characterization of Verteporfin as an OSR1 kinase inhibitor. (A) Verteporfin inhibits OSR1 T185E in vitro in an ATP-independent manner. 
(B) and (C) The effect of MgCl2 concentration on the ability of Verteporfin to inhibit OSR1 T185E. (D) Verteporfin does not exhibit any in vitro inhibition of the 
constitutively active seine/threonine protein kinase MST3. (E) and (F) Effect of the detergent Tween-20 on the ability of Verteporfin to inhibit OSR1 T185E. All of 
the kinase assays were conducted using NKCC2 (1-174) as OSR1 T185E substrate. The data represents a minimum of three independent repeats and every data 
point is the average of four determinations while the error bars are ± SEM. 
Figure 4. Verteporfin inhibition of SPAK and OSR1 kinases in HEK293 
cells. The cells were treated with the vehicle (DMSO) or the indicated inhibitors, 
STOCK-1S50699 (10 μM), Closantel (20 μM) or Verteporfin at the indicated 
concentrations. After 30 min incubation, the cells’ media was changed to 
hypotonic buffer for a further 30 min after which the cells were lysed and probed 
for the indicated proteins. pNKCC1 was quantified relative to GAPDH. The data 
were reported as mean ± SEM of n = 4; *p < 0.05; ** p < 0.01. A one-way ANOVA 
test followed by Tukey’s test were used to compare the results. 
 
    
 
 
 
 
 
STOCK1S-50699 and Closantel inhibited SPAK and OSR1 
kinases as judged by NKCC1 T203, T207 and T212 
phosphorylation (Figure 4). Impressively, Verteporfin also 
inhibited NKCC1 phosphorylation at T203, T207 and T212 in a 
dose-dependent manner though more potently than STOCK1S-
50699 and Closantel, as NKCC1 phosphorylation was almost 
completely abolished at 3 µM of Verteporfin. Critically, Verteporfin 
inhibition of SPAK and OSR1 kinases did not inhibit SPAK S373 
(and OSR1 S325) phosphorylation, which is a specific WNK 
phosphorylation site. This indicated that Verteporfin is an inhibitor 
of active SPAK and OSR1 and does not inhibit WNK 
phosphorylation (and activation) of SPAK and OSR1.  
Verteporfin is predicted to bind the activation segment of 
SPAK and OSR1 
As most of the reported SPAK and OSR1 inhibitors are known to 
bind to the CCT domain of these two kinases,[10] we explored 
whether Verteporfin also binds the CCT domain. Thus, an in vitro 
kinase assay comparing Verteporfin inhibitory activity of OSR1 
T185E full length and OSR1 T185E 1-342, which lacks the CCT 
domain, was conducted (Figure 5A and B). Surprisingly, 
Verteporfin was able to inhibit both the OSR1 T185E full-length 
and OSR1 T185E 1-342 with relatively the same potency, IC50 = 
0.207 µM and 0.305 µM, respectively. This indicated that 
Verteporfin site of action is not in the CCT domain, but instead in 
the kinase domain of SPAK and OSR1.  
In order to get an idea of the site of Verteporfin binding, we used 
AutoDock[21] and performed in silico docking of Verteporfin into 
the crystal structure of OSR1 kinase domain (PDB ID; 2VWI), 
which is composed of four symmetrical OSR1 molecules 
arranged as pairs of dimers.[22] At the molecular level, the 
interaction between the different OSR1 homodimers is mediated 
by a series of hydrophobic interactions that involve Trp192, 
Met193, Leu197, and Met198 from helix aEF are occupying a 
hydrophobic pocket made up from-residues Met233, Val235, 
Leu236, and Leu240 (helix aG), residues Trp211 and Ile215 (helix 
aF) of the neighboring molecule (Figure 5C). Although the OSR1 
kinase domain has been shown to be monomeric in solution, 
some reports the observation of OSR1 kinase domain forms 
oligomers in vivo.[23] Despite the fact that OSR1 is activated by 
WNK phosphorylation, the interactions between OSR1 
homodimers is suggested to contribute to the activation of OSR1 
akin to that seen with other protein kinases such as the checkpoint 
kinase 2 (CHK2), lymphocyte-oriented kinase (LOK) and Ste20-
like kinase (SLK).[24] Interestingly, the docking results revealed 
that Verteporfin binds to the flexible domain-exchanged kinase 
dimer, the site in which the activation segment from each 
monomer extends to form an extensive intermolecular interface 
Figure 5. Verteporfin inhibits full length OSR1 T185E by binding to its kinase domain. (A) 0.2 μM recombinant full-length human OSR1 T185E 1-527 was 
purified from E.coli was used to phosphorylate the peptide substrate CATCHtide (0.25 mM) in vitro for 30 minutes at 30 °C. 0.1 mM ATP and 10 mM MgCl2 were 
used in the assay. (B) As in A, but using the CCT truncated recombinant human OSR1 T185E 1-342 instead of the full-length OSR1. Data presented as average 
of four determinations ± SEM. (C) Docking of Verteporfin (cyan) in the OSR1 kinase domain (PDB ID: 2VWI) shows that it binds to a hydrophobic pocket formed 
by residues from α-helix G (red) and α-helix F (green). This pocket is called the domain-exchanged kinase dimer, the site for hydrophobic interaction between 
residues from α-helix EF (blue) of the activation segment of one monomer of OSR1 to another monomer. (D) AutoDock 2D representation of the interaction of 
Verteporfin with residues at the binding site. 
    
 
 
 
 
 
(Figure 5C). As shown in Figure 5D, Verteporfin is predicted to 
form hydrogen bonding with tyrosine 204 (Tyr204) and arginine 
279 (Arg279) as well as p-p stacking between tryptophan 211 and 
the isoindole bicyclic ring of Verteporfin. 
Since Verteporfin showed an ability to inhibit eight other protein 
kinases as discussed above, we also used molecular modelling 
to explore where Verteporfin binds to these protein kinases. 
Indeed, we docked Verteporfin into the structures of four protein 
kinases with crystal structure available in the PDB database 
(Supplementary Figure S9). Akin to what was seen with OSR1, 
Verteporfin was predicted in silico not to bind these kinases at 
their ATP sites. In some cases, e.g. MAP4K3, Verteporfin was 
predicted to bind the dimerization domain of this kinase. Although 
these in silico predictions seem promising, they need to be further 
confirmed by crystallography or mutagenesis studies. 
    
 
Discussion  
The compelling in vivo evidence linking the inhibition of SPAK and 
OSR1 kinases to the regulation of electrolyte balance[7] has made 
these two protein kinases very attractive molecular targets in the 
discovery of new antihypertensive drugs.[10] This novel approach 
for lowering blood pressure became more relevant following the 
discovery of notable adverse effects associated with the use of 
WNK kinase inhibitors.[11a] This may be explained by the lack of 
specificity of these WNK inhibitors across the four humans WNK 
isoforms[10] and the diverse physiological roles these protein 
kinases play in humans].[25] The advantage of targeting and 
inhibiting SPAK and OSR1 kinases instead of WNK kinases is the 
relative ease of achieving selectivity between these two kinases 
as they only share 68% sequence similarity.[2]  
To discover SPAK and OSR1 kinase inhibitors, we developed a 
robust OSR1 T185E in vitro kinase assay compatible with HTS 
technologies and used it to screen a library of 1,200 FDA-
approved drugs. This led to the identification of Verteporfin as a 
potent inhibitor of the constitutively active OSR1 T185E. Notably, 
this agent also inhibited SPAK T233E in similar potency. Although 
the activity of Verteporfin has been suggested to be affected by 
light, the inhibition of OSR1 T185E by Verteporfin was not 
significantly affected by light as there was only a 3-fold decrease 
in the inhibitory effect when the kinase activity was carried out in 
the dark. In terms of the mechanism of inhibition, in silico 
modelling indicated that Verteporfin inhibits SPAK and OSR1 
kinases by binding to their kinase domain instead of their CCT 
domains. This was an interesting finding as reported SPAK and 
OSR1 kinase inhibitors bind the CCT domain of these two 
kinases.[10] In particular, reported SPAK and OSR1 kinase 
inhibitors, e.g. STOCK50699, bind the primary pocket of these 
kinases and thus prevent their binding and activation by their 
upstream kinases, WNKs.[12a] Other SPAK and OSR1 inhibitors 
such as Rafoxanide are suggested to produce their inhibitory 
effects by binding the secondary pocket of SPAK and OSR1 
kinases.[12c] Unlike these inhibitors, molecular modelling studies 
suggested that Verteporfin binds an allosteric site adjacent to the 
kinase domain and the inhibition effect was ATP-independent. 
This type of allosteric inhibition already exists with other kinase 
inhibitors. Probably the most similar to this is that of allosteric 
WNK inhibitors, which also bind to a site adjacent to the ATP 
binding pocket but are unaffected by ATP binding.[11b] The unique 
observation made regarding the inhibition of SPAK and OSR1 
kinases is that they bind the flexible domain-exchanged kinase 
dimer. This domain is believed to mediate OSR1 
autophosphorylation,[22] and hence may explain how Verteporfin 
inhibits SPAK and OSR1 kinases. The fact that Verteporfin is 
likely to bind the flexible domain may also explain our continuous 
failed efforts of co-crystallizing SPAK and OSR1 kinase domains 
bound to Verteporfin. As the inhibition of SPAK and OSR1 kinases 
is known to lower blood pressure,[26] Verteporfin’s ability to inhibit 
these two kinases may explain some recent reports on the low 
blood pressure observed in animals that underwent treatment 
with Verteporfin.[27] 
The screening of Verteporfin against a panel of 140 protein 
kinases indicated that it also potently inhibited a range of protein 
kinases that are implicated in many important physiological 
processes. Some of the proteins these proteins have been 
implicated in inflammation, immune responses and cancer, e.g. 
IKKe,[28] MST2,[29] ULK1,[30] and MAP4K3[31]. Notably, the 
inhibition of the protein kinase MST2, a component of the Hippo 
signalling pathway,[32] may contribute to the previously reported 
anticancer activities[33] of Verteporfin that have been attributed to 
targeting this signalling cascade, specifically the inhibition of 
TEAD (Transcriptional Enhancer Associate Domain) interaction 
with YAP (Yes-Associated Protein).[34] Nevertheless, 
Verteporfin’s ability to inhibit a selection of protein kinases may 
lead to undesired side effects and could complicate the ongoing 
in vivo studies examining the pharmacological properties of this 
clinical agent.[35]  
Conclusion 
In this work, we showed that the clinically used agent Verteporfin 
is a potent inhibitor of SPAK and OSR1 kinases in vitro and in 
cells. It inhibits these kinases in an ATP-independent manner 
through the binding to a site remote from their CCT domains. In 
silico modelling indicated that Verteporfin binds the flexible 
dimerization domain of SPAK and OSR1. Although in a kinase 
screen panel, Verteporfin also inhibited eight other protein 
kinases, it still has the potential to be a powerful tool in studying 
SPAK and OSR1 signaling as to date it is the most potent reported 
inhibitor of these two important protein kinases. 
Experimental Section 
Reagents. Verteporfin (94% purity), its analogues [protoporphyrin IX 
dimethyl ester (90% purity) and 2,3,7,8,12,13,17,18-Octaethyl-21H,23H-
porphine (97% purity)], Closantel, Rafoxanide, tissue culture and protein 
expression reagents were purchased from Sigma–Aldrich. GST 
PreScission protease enzyme and glutathione-sepharose beads were 
purchased from GE Healthcare. CATCHtide were purchased from GLS 
Peptide Synthesis (China). The ADP-Glo™ Assay was purchased from 
Promega (UK). STOCK1S-50699 and DNA clones were purchased from 
the MRC PPU Services and Reagents (Dundee, UK).  
Buffers. Cell lysis buffer: 50 mM Tris:HCl (pH 7.5), 1 mM EDTA, 1 mM 
EGTA, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM 
sodium orthovanadate, 1% (w/v) Nonidet P40, 0.27mM sucrose 
supplemented with fresh 0.1% (v/v) 2-mercaptoethanol, 0.1 mM PMSF, 1 
mM benzamidine. Bacterial lysis buffer: 50 mM Tris:HCl (pH 7.5), 150 mM 
NaCl, 1 mM EGTA, 1 mM EDTA, 0.27 M sucrose supplemented with fresh 
0.1 mM PMSF, 1 mM benzamidine, 0.5 mg/mL lysosome, 0.3 mg/mL 1 
DNase and 0.01% (v/v) 2-mercaptoethanol. Buffer A: 50 mM Tris:HCl (pH 
7.5), 0.1 mM EGTA supplemented with fresh 0.1% (v/v) 2-
mercaptoethanol. Normal buffer: Consists of bacterial lysis buffer without 
lysozyme and DNase. High-salt buffer: normal buffer with 500 mM NaCl. 
Protein elution buffer: buffer A (pH 8), 150 mM NaCl and 20 mM reduced 
    
 
 
 
 
 
glutathione or preScission protease enzyme. TBS-T buffer: 50 mM 
Tris:base (pH 7.5), 150 mM NaCl and 0.2% (v/v) Tween-20. Running 
buffer: 34.6 mM SDS, 25 mM Tris·Base and 1.92M glycine. Transfer 
buffer: 48 mM Tris·Base, 39 mM glycine containing 20% (v/v) methanol. 
Hypotonic low chloride buffer: Consists of 67.5 mM sodium gluconate, 2.5 
mM potassium gluconate, 0.25 mM CaCl2, 0.25 mM MgCl2, 0.5 mM 
Na2HPO4, 0.5 mM Na2SO4 and 7.5 mM HEPES. SDS sample buffer (4X): 
Consists of 40% glycerol, 240 mM Tris:HCl (pH 6.8), 8% SDS, 0.04% 
bromophenol blue and 5% 2-mercaptoethanol. 
Antibodies. Anti-SPAK pS373 [S670B], anti-total-SPAK [S551D], anti-
NKCC1 pT203+pT207+pT212) [S763B] and anti-total NKCC1 [DU 6146] 
were purchased from the MRC PPU Services and Reagents (Dundee, UK). 
Anti-GAPDH [2118] was purchased from Cell Signalling Technology. Anti-
rabbit [31460] and anti-sheep [31480] secondary antibodies conjugated to 
HRP were purchased from Thermo Scientific. 
DNA plasmids. pGEX-OSR1 T185E full-length [DU6231], pGEX-OSR1 
T185E (1-342) [DU6363], pGEX-SPAK T233E full-length [DU6246] and 
pGEX-NKCC2 (1-174) [DU13763] were all purchased from the MRC PPU 
Services and Reagents (Dundee, UK).  
Protein expression and purification. pGEX-6P-1 constructs encoding N-
terminal GST-tagged proteins were transformed into BL21 (DE3) E.coli. 
One litre of transformed BL21 E. coli cells was grown at 37 °C at 180 rpm 
in Luria Broth media containing 100 μg/mL ampicillin until reaching an 
OD600 of 0.7. Protein expression was induced by addition of 250 μM IPTG. 
Then, cells were cultured for an additional 16 hours at 26 °C at 180 rpm 
before collecting them by centrifugation at 3,500g at 4 °C for 30 minutes. 
The cell pellet was resuspended in 50 mL ice-cold bacterial lysis buffer and 
incubated in ice path at 4°C for 30 minutes. Bacteria were lysed by 
sonication, for 30 seconds on/off round six times. Lysates were centrifuged 
at 25000g at 4 °C for 30 minutes. The supernatant was collected and 
incubated overnight with 2 mL/L of glutathione-Sepharose beads (pre-
washed with lysis buffer) to affinity purified GST-tagged proteins. The 
beads were then washed twice with normal buffer, high salt buffer and 
buffer A, respectively. GST proteins were eluted with elution buffer 
containing 20mM reduced L-glutathione. NKCC2 1-174 was eluted with 
elution buffer containing preScission protease enzyme. Proteins were 
concentrated to 100-500 μL with amicon ultra-15 centrifugal filter units (3 
kDa and 10 kDa cut-off). Proteins concentrations were measured by 
Bradford assay. Proteins yield and purity were confirmed by SDS-PAGE 
and Coomassie staining using different concentrations of bovine serum 
albumin (BSA) as standards.[5] 
Cell culture and treatment with inhibitors. Human embryonic kidney 
293 cells were cultured on 6-well plates in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 2 mM 
L-glutamine, 100 units/mL penicillin and 0.1 mg/mL streptomycin at 37 °C 
in a humidified 5% CO2 incubator. For the inhibition assay, 75% confluent 
cells were incubated with DMSO as a vehicle control or compounds at 
indicated concentrations for 30 minutes using Closantel and STOCK1S-
50699 as positive controls. Then WNK signalling was stimulated with low-
chloride hypotonic buffer for 30 minutes. Then cells were washed with 1 
mL phosphate-buffered saline (PBS) and lysed subsequently with 150 μL 
ice-cold cells lysis buffer per well and centrifuged at 12,000g at 4 °C for 10 
minutes to collect the proteins. The proteins concentrations were 
measured using standard Bradford assay. Then, protein samples were 
denatured for 5 minutes at 90 °C with 1X SDS buffer and subjected to 
SDS-PAGE. Final DMSO concentration was 0.1%. 
Immunoblotting. SDS Samples were subjected to 10% SDS-PAGE. Then 
proteins transferred from gel on to nitrocellulose membranes. The 
membranes were then blocked with blocking buffer for 45 minutes on 
platform shaker. Then, the membranes were incubated with primary 
-SPAK (2 μg/mL), anti-total-SPAK (2 μg/mL), anti-phospho-antibody (anti
NKCC1 (2 μg/mL) in 5% (w/v) total -NKCC1 (2 μg/mL) and anti-phospho
GST (1:500) -GAPDH (1:1000) and anti-T, anti-dried skimmed milk in TBS
 T) for 1 hour at room-in 10% (w/v) bovine serum albumin (BSA) /TBS
C. Then membranes were washed four °temperature or overnight at 4 
sheep -bated with secondary antibody (antiT and incu-times with TBS
rabbit (1:2500) -T and anti-(1:2000) in 5% (w/v) dried skimmed milk in TBS
T). The membranes then washed four times with -in 10% (w/v) BSA/TBS
T. The detection was done by adding enhanced chemiluminescence -TBS
radiographic film. The -t to the membranes and developing an autoreagen
bands intensities were and quantified by ImageJ software (NIH) and 
analysis with GraphPadPrism 6.0. 
Docking studies. Autodock [31] Vina 1.1.2 was used to dock Verteporfin 
into OSR1 kinase domain (PDB ID: 2VWI). Verteporfin SDF file was 
download from PubChem (PubChem CID: 5362420). The protein and 
compound PDB files were initially prepared and visualized with Discovery 
Studio 4.5 (Accelrys, San Diego, CA, USA) and then converted into 
PDBQT format using AutoDock Tool 1.5.6.[36] Unbiased docking approach 
in which the grid box was centralized to cover the whole protein, was 
performed using default settings as described by developers. The docking 
results were visualized and analyzed using Discovery Studio 4.5 and 
PyMOL Molecular Graphics System 1.3. 
ADP-Glo™ (HTS) kinase assay. The assay was performed in 384-well 
plate format by incubating 1 µl of either DMSO or different concentrations 
of the inhibitors with 0.2 µM purified proteins in a 5 µL total reaction volume 
containing 50 mM Tris-HCl, 10 mM MgCl2, 0.1% (v/v) 2-mercaptoethanol, 
0.05% Tween-20, and 0.1 mM ATP in buffer A employing GST cleaved 
NKCC2 1-174 or CATCHtide (RRHYYYDTHTNTYYLR-TFGHNTRR) as 
substrates at 5 µM and 250 µM final concentrations, respectively. The 
kinase reaction was carried out in a white round-bottom 384-well plate 
(Greiner) at 30 °C for 30 minutes with gentle agitation on microplate shaker 
incubator. The kinase activity was assayed using ADP-GloÔ kinase assay 
according to the manufacturer's protocol.[14] The plate was subsequently 
read on a BMG FLUOstar Omega plate reader. In the case of running the 
kinase assay in the dark, the kinase assay plate was covered with 
aluminium foil prior to adding Verteporfin and then kept covered during the 
running of the assay and until the reading of the assay results in the BMG 
FLUOstar Omega plate reader. For chemical library screening, assay was 
performed in duplicate following the HTS screening data illustrated below. 
For inhibition studies, increasing concentrations of each compound were 
tested in four replicates with at least ten to eighteen data points per curve. 
For studying the effect of Verteporfin on MST3 kinase, the kinase assay 
was conducted with the same protocol using 0.1 µM of recombinant MST3 
(1 - 431) [MRC PPU Services and Reagents (Dundee, UK)] with 0.3 mg/mL 
Myelin basic protein (MBP) (Sigma Aldrich) as a substrate as reported.[5] 
Curve fitting and data analysis was completed with GraphPadPrism 6.0. 
Final DMSO concentration was 4%. 
HTS assay performance. The assay parameters were calculated 
according to the following equations[17]: 
Where s and µ are the standard deviations and means of the positive (total 
reaction mixture with NKCC2 1-174 substrate in absence of OSR1 T185E 
kinase) and negative (total reaction mixture with NKCC2 (1-174) substrate 
in presence of OSR1 T185E kinase) controls, respectively. The reported 
values were the average of three independent experiments of sixteen 
replicates performed on different days. 
Post screening, in addition to the Z’ factor, the signal window (SW) and 
coefficient of variation (CV%) were determined for each plate based on the 
following equations: 
The reported values for each plate were the average for two plates with 
sixteen replicates per each. 
Acknowledgements  
We are also grateful to the Protein Expression Facility (University 
of Birmingham) for help with protein production. M.A.A. is funded 
 
 
 
 
!" = 	1 −	µ	negative −µ	positive	σ	positive  
!"%= 	&σ	negative		µ	negative0 
 
 
 
!" = 	1 −	3	σ	positive+ 	3	σ	negative	|	µ	positive− 		µ	negative|  
! "⁄ = 	1 −	µ	negative − µ	positive	σ	positive  
! "⁄ = 	1 −	µ	negative	µ	positive  
    
 
 
 
 
 
by a PhD studentship from the Ministry of Education in Saudi 
Arabia and Prince Sattam Bin Abdulaziz University. 
Keywords: SPAK • OSR1 • WNK • High throughput • Inhibitor 
References 
[1] a) D. R. Alessi, J. Zhang, A. Khanna, T. Hochdorfer, Y. Shang, 
K. T. Kahle, Sci. Signal. 2014, 7, re3; b) J. Hadchouel, D. H. 
Ellison, G. Gamba, Ann. Rev. Physiol. 2016, 78, 367-389; c) C. 
Richardson, D. R. Alessi, J. Cell Sci. 2008, 121, 3293-3304. 
[2] A. C. Vitari, J. Thastrup, F. H. Rafiqi, M. Deak, N. A. Morrice, H. 
K. Karlsson, D. R. Alessi, Biochem. J. 2006, 397, 223-231. 
[3] a) A. Zagorska, E. Pozo-Guisado, J. Boudeau, A. C. Vitari, F. 
H. Rafiqi, J. Thastrup, M. Deak, D. G. Campbell, N. A. Morrice, 
A. R. Prescott, D. R. Alessi, J. Cell Biol. 2007, 176, 89-100; b) 
T. Moriguchi, S. Urushiyama, N. Hisamoto, S. Iemura, S. 
Uchida, T. Natsume, K. Matsumoto, H. Shibuya, J. Biol. Chem. 
2005, 280, 42685-42693. 
[4] a) H. Miyamoto, A. Matsushiro, M. Nozaki, Mol. Reprod. Dev. 
1993, 34, 1-7; b) M. Nozaki, Y. Onishi, S. Togashi, H. Miyamoto, 
DNA Cell Biol. 1996, 15, 505-509. 
[5] B. M. Filippi, P. de los Heros, Y. Mehellou, I. Navratilova, R. 
Gourlay, M. Deak, L. Plater, R. Toth, E. Zeqiraj, D. R. Alessi, 
EMBO J. 2011, 30, 1730-1741. 
[6] F. H. Wilson, S. Disse-Nicodeme, K. A. Choate, K. Ishikawa, C. 
Nelson-Williams, I. Desitter, M. Gunel, D. V. Milford, G. W. 
Lipkin, J. M. Achard, M. P. Feely, B. Dussol, Y. Berland, R. J. 
Unwin, H. Mayan, D. B. Simon, Z. Farfel, X. Jeunemaitre, R. P. 
Lifton, Science  2001, 293, 1107-1112. 
[7] M. Murthy, T. Kurz, K. M. O'Shaughnessy, Cell. Mol. Life Sci. 
2017, 74, 1261-1280. 
[8] a) A. Ohta, F. R. Schumacher, Y. Mehellou, C. Johnson, A. 
Knebel, T. J. Macartney, N. T. Wood, D. R. Alessi, T. Kurz, 
Biochem. J. 2013, 451, 111-122; b) M. Wakabayashi, T. Mori, 
K. Isobe, E. Sohara, K. Susa, Y. Araki, M. Chiga, E. Kikuchi, N. 
Nomura, Y. Mori, H. Matsuo, T. Murata, S. Nomura, T. Asano, 
H. Kawaguchi, S. Nonoyama, T. Rai, S. Sasaki, S. Uchida, Cell 
Rep. 2013, 3, 858-868; c) S. Shibata, J. Zhang, J. Puthumana, 
K. L. Stone, R. P. Lifton, Proc. Nat. Acad. Sci. USA 2013, 110, 
7838-7843. 
[9] a) L. M. Boyden, M. Choi, K. A. Choate, C. J. Nelson-Williams, 
A. Farhi, H. R. Toka, I. R. Tikhonova, R. Bjornson, S. M. Mane, 
G. Colussi, M. Lebel, R. D. Gordon, B. A. Semmekrot, A. Poujol, 
M. J. Valimaki, M. E. De Ferrari, S. A. Sanjad, M. Gutkin, F. E. 
Karet, J. R. Tucci, J. R. Stockigt, K. M. Keppler-Noreuil, C. C. 
Porter, S. K. Anand, M. L. Whiteford, I. D. Davis, S. B. Dewar, 
A. Bettinelli, J. J. Fadrowski, C. W. Belsha, T. E. Hunley, R. D. 
Nelson, H. Trachtman, T. R. Cole, M. Pinsk, D. Bockenhauer, 
M. Shenoy, P. Vaidyanathan, J. W. Foreman, M. Rasoulpour, 
F. Thameem, H. Z. Al-Shahrouri, J. Radhakrishnan, A. G. 
Gharavi, B. Goilav, R. P. Lifton, Nature 2012, 482, 98-102; b) 
H. Louis-Dit-Picard, J. Barc, D. Trujillano, S. Miserey-Lenkei, N. 
Bouatia-Naji, O. Pylypenko, G. Beaurain, A. Bonnefond, O. 
Sand, C. Simian, E. Vidal-Petiot, C. Soukaseum, C. Mandet, F. 
Broux, O. Chabre, M. Delahousse, V. Esnault, B. Fiquet, P. 
Houillier, C. I. Bagnis, J. Koenig, M. Konrad, P. Landais, C. 
Mourani, P. Niaudet, V. Probst, C. Thauvin, R. J. Unwin, S. D. 
Soroka, G. Ehret, S. Ossowski, M. Caulfield, P. Bruneval, X. 
Estivill, P. Froguel, J. Hadchouel, J. J. Schott, X. Jeunemaitre, 
Nature Genet. 2012, 44, 456-460. 
[10] M. A. AlAmri, H. Kadri, B. A. Dhiani, S. Mahmood, A. Elzwawi, 
Y. Mehellou, ChemMedChem 2017, 12, 1677-1686. 
[11] a) K. Yamada, H. M. Park, D. F. Rigel, K. DiPetrillo, E. J. 
Whalen, A. Anisowicz, M. Beil, J. Berstler, C. E. Brocklehurst, 
D. A. Burdick, S. L. Caplan, M. P. Capparelli, G. Chen, W. Chen, 
B. Dale, L. Deng, F. Fu, N. Hamamatsu, K. Harasaki, T. Herr, 
P. Hoffmann, Q. Y. Hu, W. J. Huang, N. Idamakanti, H. Imase, 
Y. Iwaki, M. Jain, J. Jeyaseelan, M. Kato, V. K. Kaushik, D. 
Kohls, V. Kunjathoor, D. LaSala, J. Lee, J. Liu, Y. Luo, F. Ma, 
R. Mo, S. Mowbray, M. Mogi, F. Ossola, P. Pandey, S. J. Patel, 
S. Raghavan, B. Salem, Y. H. Shanado, G. M. Trakshel, G. 
Turner, H. Wakai, C. Wang, S. Weldon, J. B. Wielicki, X. Xie, L. 
Xu, Y. I. Yagi, K. Yasoshima, J. Yin, D. Yowe, J. H. Zhang, G. 
Zheng, L. Monovich, Nature Chem. Biol. 2016, 12, 896-898; b) 
K. Yamada, J. H. Zhang, X. Xie, J. Reinhardt, A. Q. Xie, D. 
LaSala, D. Kohls, D. Yowe, D. Burdick, H. Yoshisue, H. Wakai, 
I. Schmidt, J. Gunawan, K. Yasoshima, Q. K. Yue, M. Kato, M. 
Mogi, N. Idamakanti, N. Kreder, P. Drueckes, P. Pandey, T. 
Kawanami, W. Huang, Y. I. Yagi, Z. Deng, H. M. Park, ACS 
Chem. Biol. 2016, 11, 3338-3346. 
[12] a) T. Mori, E. Kikuchi, Y. Watanabe, S. Fujii, M. Ishigami-Yuasa, 
H. Kagechika, E. Sohara, T. Rai, S. Sasaki, S. Uchida, 
Biochem. J. 2013, 455, 339-345; b) E. Kikuchi, T. Mori, M. 
Zeniya, K. Isobe, M. Ishigami-Yuasa, S. Fujii, H. Kagechika, T. 
Ishihara, T. Mizushima, S. Sasaki, E. Sohara, T. Rai, S. Uchida, 
J. Am. Soc. Nephrol. 2015, 26, 1525-1536; c) M. A. AlAmri, H. 
Kadri, L. J. Alderwick, N. S. Simpkins, Y. Mehellou, 
ChemMedChem 2017, 12, 639-645. 
[13] P. de Los Heros, D. R. Alessi, R. Gourlay, D. G. Campbell, M. 
Deak, T. J. Macartney, K. T. Kahle, J. Zhang, Biochem. J. 2014, 
458, 559-573. 
[14] H. Zegzouti, M. Zdanovskaia, K. Hsiao, S. A. Goueli, Assay 
Drug Dev. Techn. 2009, 7, 560-572. 
[15] A. C. Vitari, M. Deak, N. A. Morrice, D. R. Alessi, Biochem. J. 
2005, 391, 17-24. 
[16] C. Richardson, K. Sakamoto, P. de los Heros, M. Deak, D. G. 
Campbell, A. R. Prescott, D. R. Alessi, J. Cell Sci. 2011, 124, 
789-800. 
[17] J. H. Zhang, T. D. Chung, K. R. Oldenburg, J. Biomol. Scr. 1999, 
4, 67-73. 
[18] a) M. A. Awan, S. A. Tarin, Surgeon 2006, 4, 231-236; b) C. 
Fenton, C. M. Perry, Drugs Aging 2006, 23, 421-445. 
[19] L. R. Pearce, D. Komander, D. R. Alessi, Nature Rev. Mol. Cell 
Biol. 2010, 11, 9-22. 
[20] a) E. Donohue, A. D. Balgi, M. Komatsu, M. Roberge, PLoS One 
2014, 9, e114964; b) E. K. Konstantinou, S. Notomi, C. 
Kosmidou, K. Brodowska, A. Al-Moujahed, F. Nicolaou, P. 
Tsoka, E. Gragoudas, J. W. Miller, L. H. Young, D. G. Vavvas, 
Sci. Rep. 2017, 7, 46581. 
[21] D. S. Goodsell, G. M. Morris, A. J. Olson, J. Mol. Recognit. 
1996, 9, 1-5. 
[22] F. Villa, M. Deak, D. R. Alessi, D. M. van Aalten, Proteins 2008, 
73, 1082-1087. 
[23] A. N. Anselmo, S. Earnest, W. Chen, Y. C. Juang, S. C. Kim, Y. 
Zhao, M. H. Cobb, Proc. Nat. Acad. Sci. USA 2006, 103, 10883-
10888. 
[24] a) A. W. Oliver, A. Paul, K. J. Boxall, S. E. Barrie, G. W. Aherne, 
M. D. Garrett, S. Mittnacht, L. H. Pearl, EMBO J. 2006, 25, 
3179-3190; b) A. C. Pike, P. Rellos, F. H. Niesen, A. Turnbull, 
A. W. Oliver, S. A. Parker, B. E. Turk, L. H. Pearl, S. Knapp, 
EMBO J. 2008, 27, 704-714. 
[25] a) A. R. Rodan, A. Jenny, Curr. Top. Dev. Biol. 2017, 123, 1-47; 
b) M. Shekarabi, J. Zhang, A. R. Khanna, D. H. Ellison, E. 
Delpire, K. T. Kahle, Cell Metab. 2017, 25, 285-299; c) C. S. 
Wilson, A. A. Mongin, Neurosc. Lett. 2018, DOI: 
10.1016/j.neulet.2018.01.012. 
[26] F. H. Rafiqi, A. M. Zuber, M. Glover, C. Richardson, S. Fleming, 
S. Jovanovic, A. Jovanovic, K. M. O'Shaughnessy, D. R. Alessi, 
EMBO Mol. Med. 2010, 2, 63-75. 
[27] S. K. Charisis, I. Naoumidi, H. S. Ginis, M. K. Tsilimbaris, Invest. 
Ophthalmol. Vis. Sci. 2007, 47, 3970. 
[28] K. Verhelst, L. Verstrepen, I. Carpentier, R. Beyaert, Biochem. 
Pharmacol. 2013, 85, 873-880. 
[29] E. O'Neill, W. Kolch, Cell Cycle 2005, 4, 365-367. 
[30] D. Saleiro, E. M. Kosciuczuk, L. C. Platanias, Cytokine Growth 
Factor Rev. 2016, 29, 17-22. 
[31] H. C. Chuang, X. Wang, T. H. Tan, Adv. Immunol. 2016, 129, 
277-314. 
[32] D. Pan, Dev. Cell 2010, 19, 491-505. 
[33] F. Gibault, M. Corvaisier, F. Bailly, G. Huet, P. Melnyk, P. 
Cotelle, Curr. Med. Chem. 2016, 23, 1171-1184. 
[34] Y. Liu-Chittenden, B. Huang, J. S. Shim, Q. Chen, S. J. Lee, R. 
A. Anders, J. O. Liu, D. Pan, Genes  Dev. 2012, 26, 1300-1305. 
[35] a) M. T. Huggett, M. Jermyn, A. Gillams, R. Illing, S. Mosse, M. 
Novelli, E. Kent, S. G. Bown, T. Hasan, B. W. Pogue, S. P. 
Pereira, Br. J. Cancer 2014, 110, 1698-1704; b) J. Feng, J. Gou, 
J. Jia, T. Yi, T. Cui, Z. Li, OncoTargets Ther. 2016, 9, 5371-
5381. 
[36] M. F. Sanner, J. Mol. Graph. Model. 1999, 17, 57-61. 
    
 
 
 
 
 
 
Table of Contents  
 
 
SPAK and OSR1 are two 
serine/threonine protein kinases that 
control the function of a series of ion 
co-transporters and hence cellular 
electrolyte balance. Animal models 
with impaired SPAK and OSR1 
signalling have been shown to exhibit 
reduced blood pressure. In this work, 
we report the identification and 
characterisation of the clinically used 
agent Verteporfin as a potent inhibitor 
of SPAK and OSR1 kinases.   
    Mubarak A. AlAmri, Hachemi Kadri, 
Luke J. Alderwick, Mark Jeeves, Youcef 
Mehellou,* 
Page No. – Page No. 
The Photosensitizing Clinical Agent 
Verteporfin is an Inhibitor of SPAK 
and OSR1 Kinases 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Verteporfin (VisudyneTM)
OSR1 and SPAK inhibitor
in vitro IC50 = 200-330 nM
    
 
 
 
 
 
 
 
Supporting Information 
 
 
 
 
 
 
 
Figure S1. SDS-PAGE gels of the proteins used in this study. (A) GST-OSR1 T185E FL (B) GST-OSR1 T185E 
1-342 (C) NKCC2 1-174 purifications using Coomassie blue stain. BSA (Sigma Aldrich, cat#A2153, purity 
≥ 96% (agarose gel electrophoresis) was used at different concentrations as standards for proteins yield 
and purity determination. 
 
 
 
Figure S2. Optimization of the in vitro OSR1 T185E HTS ADP-GLO™ kinase assay using CATCHtide as a 
substrate. The in vitro kinase assay was performed in 384-well plate in a total volume of 5 µl comprising 
0.2 µM OSR1 T185E full length or truncated OSR1 T185E 1-342, 250 µM CATCHtide. 50 mM Tris-HCl, 10 
mM MgCl2, 0.1% (v/v) 2-mercaptoethanol, 0.05% Tween-20, and 0.1 mM ATP in buffer A. 
 
    
 
 
 
 
 
 
Figure S3. Optimization of the in vitro OSR1 T185E HTS ADP-GLO™ kinase assay using human NKCC2 
(1-174) as a substrate. The in vitro kinase assay was performed in 384-well plate in a total volume of 5 
µl comprising 0.2 µM OSR1 T185E full length or truncated OSR1 T185E 1-342, 5 µM recombinant human 
NKCC2 (1-174). 50 mM Tris-HCl, 10 mM MgCl2, 0.1% (v/v) 2-mercaptoethanol, 0.05% Tween-20, and 0.1 
mM ATP in buffer A. 
 
 
 
 
Figure S4. Post-screening assay parameters. Post screening assay parameters. (Left)The zʹ factor, 
(Middle) signal window (SW), and (Right) coefficient of variation (CV) of each plate were calculated and 
then compared with the minimum pass criteria. Dashed lines show the minimum pass criteria (zʹ > 0.5, 
SW > 2, CV < 20%). 
 
    
 
 
 
 
 
 
Figure S5. In vitro inhibition of SPAK T233E by Verteporfin. 0.2 µM recombinant full-length human SPAK 
T185E 1-547 was purified from E.coli was used to phosphorylate the peptide substrate CATCHtide (250 
µM) in vitro for 30 minutes at 30 °C. 0.1 mM ATP and 10 mM MgCl2 were used in the assay as described 
under the Reagents and Methods section. 
 
 
 
 
Figure S6. Verteporfin analogues with porphyrin rings do not inhibit OSR1 T185E in vitro. Two 
analogues of Verteporfin namely 2,3,7,8,12,13,17,18-Octaethyl-21H,23H-porphine (A) and 
protoporphyrin IX dimethyl ester (B) were used. The kinase assay was performed at 30 °C for 30 minutes 
by incubating 0.2 µM OSR1 T185E with increasing concentrations of Verteporfin in presence or absence 
of 5 molar excess of MO25 (1 µM) in a total assay volume of 5 µL. 250 µM CATCHtide, 0.1 mM ATP and 
10 mM MgCl2 were also used in the assay. 
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Figure S7. Verteporfin does not affect SPAK and OSR1 activation by MO25. The kinase assay was 
performed at 30 °C for 30 minutes by incubating 0.2 µM OSR1 T185E with increasing concentrations of 
Verteporfin in presence or absence of 5 molar excess of MO25 (1 µM) in a total assay volume of 5 µL. 
250 µM CATCHtide, 0.1 mM ATP and 10 mM MgCl2 were also used in the assay. 
 
 
Figure S8. Light does not significantly affect Verteporfin’s ability to inhibit OSR1 T18E in vitro. The 
kinase assay was performed at 30 °C for 30 minutes by incubating 0.2 µM OSR1 T185E with increasing 
concentrations of Verteporfin in a total assay volume of 5 µL. 5 µM recombinant human NKCC2 (1-174), 
0.1 mM ATP and 10 mM MgCl2 were also used in the assay. For dark assay conditions, the assay plate 
was covered in aluminum foil prior to the addition of Verteporfin and during the assay until the assay 
was finished the plate was being read. 
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Figure S9. In Silico modelling indicates that Verteporfin does not bind the ATP pocket of hit protein 
kinases. A) Ribbon representation of Verteporfin (pink) bound to MAP4K3 (grey). B)  Ribbon 
representation of structure alignment of the crystal structures of MAP4K3 kinase (PDB: 5J5T) (grey) and 
OSR1 kinase 1-303 (PDB: 2VWI) (yellow). Glycine rich loop and hinge region are shown in red and green 
color, respectively. Catalytic lysine of MAP4K3 (K45) and OSR1 (K46) are shown in cyan and pink sticks, 
A. B.
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respectively. C) Ribbon representation of Verteporfin (orange) bound to MLK1 (grey). D)  Ribbon 
representation of structure alignment of the crystal structures of MLK1 kinase (PDB: 3DTC) (grey) and 
OSR1 kinase 1-303 (PDB: 2VWI) (yellow). Glycine rich loop and hinge region are shown in red and green 
color, respectively. Catalytic lysine of MLK1 (K171) and OSR1 (K46) are shown in cyan and pink sticks, 
respectively. E) Ribbon representation of Verteporfin (cayan) bound to LCK (pink). F)  Ribbon 
representation of structure alignment of the crystal structures of LCK kinase (PDB: 2PL0) (pink) and OSR1 
kinase 1-303 (PDB: 2VWI) (yellow). Glycine rich loop and hinge region are shown in yellow and green 
color, respectively. Catalytic lysine of LCK (K273) and OSR1 (K46) are shown in blue and pink sticks, 
respectively. Similar results were found with MST2 and ULK1 in silico docking. 
 
 
